UNSPSC 51351629: Estrone acetate

This classification denotes an estrogen C20H24O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4L6USG266B, chemically known as estra-1,3,5(10)-trien-17-one, 3-(acetyloxy)-, but more generally known as estrone acetate, which bears US NIH Compound Identifier 3273. Most nations, for tariff and trade purposes, schedule estrone acetate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)OC1CCC2C(C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C.

UNSPSC 51351629 Estrone acetate is a Commodity code for pharmaceutical products, though recent state and local activity under this code reflects a broader procurement of generic multi-source pharmaceuticals and over-the-counter products rather than estrone acetate specifically. State and local governments are acquiring these products through cooperative purchasing agreements that route supply through authorized wholesalers, with contracts establishing pricing structures, product specifications, and compliance with manufacturing and supply-chain security standards. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body visible in recent activity, soliciting manufacturers and suppliers to serve participating state and local government facilities across multiple jurisdictions including Oregon.

MMCAP posted an RFP on January 20, 2026 (with responses due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, requiring vendors to supply through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Products must be available by May 15, 2026, with contracts effective July 1, 2026 for a two-year initial term. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for contract term, and 5 percent each on administrative fee data format compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must maintain commercial general liability of $5,000,000 per occurrence, demonstrate cGMP and Drug Supply Chain Security Act compliance, hold contractual relationships with at least two of the three authorized wholesalers with chargeback systems, and offer pricing flexibility through flat price, net price, or WAC-minus structures. No specific set-aside designations or restrictions for disadvantaged enterprises are identified in available documentation.